Danni Yu
Danni Yu
Nektar Therapeutics, Eli Lilly and Company, Purdue University
Dirección de correo verificada de
Citado por
Citado por
A Coastal Cline in Sodium Accumulation in Arabidopsis thaliana Is Driven by Natural Variation of the Sodium Transporter AtHKT1;1
I Baxter, JN Brazelton, D Yu, YS Huang, B Lahner, E Yakubova, Y Li, ...
PLoS genetics 6 (11), e1001193, 2010
Shrinkage estimation of dispersion in Negative Binomial models for RNA-seq experiments with small sample size
D Yu, W Huber, O Vitek
Bioinformatics 29 (10), 1275-1282, 2013
miR-191 and miR-135 are required for long-lasting spine remodelling associated with synaptic long-term depression
Z Hu, D Yu, Q Gu, Y Yang, K Tu, J Zhu, Z Li
Nature communications 5 (1), 3263, 2014
Expression of miRNAs and their cooperative regulation of the pathophysiology in traumatic brain injury
Z Hu, D Yu, C Almeida-Suhett, K Tu, AM Marini, L Eiden, MF Braga, J Zhu, ...
PloS one 7 (6), e39357, 2012
miR-26a and miR-384-5p are required for LTP maintenance and spine enlargement
QH Gu, D Yu, Z Hu, X Liu, Y Yang, Y Luo, J Zhu, Z Li
Nature communications 6 (1), 6789, 2015
Blocking TIM-3 in treatment-refractory advanced solid tumors: a phase Ia/b study of LY3321367 with or without an anti-PD-L1 antibody
JJ Harding, V Moreno, YJ Bang, MH Hong, A Patnaik, J Trigo, ...
Clinical Cancer Research 27 (8), 2168-2178, 2021
A phase I study of LY3009120, a pan-RAF inhibitor, in patients with advanced or metastatic cancer
RJ Sullivan, A Hollebecque, KT Flaherty, GI Shapiro, J Rodon Ahnert, ...
Molecular cancer therapeutics 19 (2), 460-467, 2020
Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced …
MW Saif, JA Knost, EG Chiorean, SRP Kambhampati, D Yu, B Pytowski, ...
Cancer chemotherapy and pharmacology 78, 815-824, 2016
High-resolution genome-wide scan of genes, gene-networks and cellular systems impacting the yeast ionome
D Yu, JMC Danku, I Baxter, S Kim, OK Vatamaniuk, O Vitek, M Ouzzani, ...
BMC genomics 13, 1-25, 2012
Safety and antitumor activity of α-PD-L1 antibody as monotherapy or in combination with α-TIM-3 antibody in patients with microsatellite instability–high/mismatch repair …
A Hollebecque, HC Chung, MJ De Miguel, A Italiano, JP Machiels, CC Lin, ...
Clinical Cancer Research 27 (23), 6393-6404, 2021
Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: a phase I study
KA Autio, CA Klebanoff, D Schaer, JSW Kauh, SF Slovin, M Adamow, ...
Clinical Cancer Research 26 (21), 5609-5620, 2020
LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose …
A Dowlati, RD Harvey, RD Carvajal, O Hamid, SJ Klempner, JSW Kauh, ...
Investigational New Drugs 39, 1057-1071, 2021
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: the PACT phase Ia/Ib trial
A Patnaik, TA Yap, HC Chung, MJ de Miguel, YJ Bang, CC Lin, WC Su, ...
Clinical Cancer Research 27 (5), 1267-1277, 2021
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with …
A Azaro, C Massard, WD Tap, PA Cassier, J Merchan, A Italiano, ...
Investigational new drugs 39, 1089-1098, 2021
Proteomic analysis of high NaCl-induced changes in abundance of nuclear proteins
J Li, JD Ferraris, D Yu, T Singh, Y Izumi, G Wang, M Gucek, MB Burg
Physiological Genomics, 2012
Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant …
KA Autio, CA Klebanoff, D Schaer, JS Kauh, SF Slovin, VS Blinder, ...
Journal of Clinical Oncology 37 (15_suppl), 2548-2548, 2019
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
NM Tannir, DC Cho, A Diab, M Sznol, MA Bilen, AV Balar, G Grignani, ...
Journal for immunotherapy of cancer 10 (4), 2022
Noise reduction in genome-wide perturbation screens using linear mixed-effect models
D Yu, J Danku, I Baxter, S Kim, OK Vatamaniuk, DE Salt, O Vitek
Bioinformatics 27 (16), 2173-2180, 2011
A first-in-human dose phase 1 study of LY3009120 in advanced cancer patients.
DS Hong, A Hollebecque, MS Gordon, KT Flaherty, G Shapiro, J Rodon, ...
Journal of Clinical Oncology 35 (15_suppl), 2507-2507, 2017
Bempegaldesleukin plus nivolumab in first-line metastatic urothelial carcinoma: results from PIVOT-02
AO Siefker-Radtke, DC Cho, A Diab, M Sznol, MA Bilen, AV Balar, ...
European urology 82 (4), 365-373, 2022
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20